Chipscreen(SH:688321) Sou Hu Cai Jing·2025-11-05 02:49Core Viewpoint - Microchip Biotech (SH688321) reported significant turnaround in profitability for the first three quarters of 2025, with a substantial increase in revenue and net profit compared to the previous year [1][2]. Financial Performance - The company's revenue for the first three quarters reached 674.16 million yuan, a year-on-year increase of 40.12% [1]. - The net profit attributable to shareholders was 70.77 million yuan, a remarkable turnaround from a loss of 51.08 million yuan in the same period last year, representing a growth of 238.53% [1]. - The net profit excluding non-recurring gains and losses was 58.44 million yuan, up 201.17% year-on-year [1]. - Basic earnings per share were reported at 0.1735 yuan [1]. Profitability Metrics - The gross margin for the first three quarters was 87.29%, a slight decrease of 0.29 percentage points year-on-year [2]. - The net profit margin improved to 10.50%, an increase of 21.12 percentage points compared to the previous year [2]. Expense Analysis - Total operating expenses for the first three quarters amounted to 504 million yuan, an increase of 49.91 million yuan from the previous year [2]. - The expense ratio was 74.73%, a decrease of 19.61 percentage points year-on-year [2]. - Sales expenses increased by 9.90%, management expenses rose by 18.93%, R&D expenses grew by 10.04%, and financial expenses increased by 8.20% [2]. Leadership Compensation - The chairman and general manager, Xianping Lu, received a salary of 2.996 million yuan in 2024, reflecting an 11.50% decrease from the previous year's salary of 3.385 million yuan [4].